NCT06557889
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06557889
Title Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (REDUCE)
Acronym REDUCE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut Claudius Regaud
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Amiens Amiens France Details
Institut Sainte Catherine Avignon France Details
Chu Bordeaux - Hopital Saint André Bordeaux France Details
Centre Jean Perrin Clermont-Ferrand France Details
Chu Limoges Limoges France Details
Centre Hospitalier Regional de Marseille Marseille France Details
CHU de Nantes Nantes France Details
Centre Antoine Lacassagne Nice France Details
Chu de Nimes Nîmes France Details
CHU Poitiers Poitiers France Details
Centre Eugène Marquis Rennes France Details
Clinique Pasteur Toulouse France Details
IUCT-O Toulouse France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field